Once again, and now for the third Friday in a row, we’ve been treated to some off-the-reservation remarks from Merck’s main man in Asia and India — Senior Vice President Ramesh Subrahmanian. [Someone — anyone — at Whitehouse Station, probably ought to call this guy (and hand him some science primers). In any event, the US NIH would certainly disagree with his remark about Hep C being cured.]
In fact, it has been known for a few years that — apparently due to greater insulin resistance rates — Asians, as a group, respond more poorly to current regimens of Hep C treatment, than do Caucasians. The same seems true of people of African descent. In a twist of very-potent irony — Mr. Subrahmanian was targeting his remarks at Merck’s emerging Asian markets.
It is possible that he was misquoted, but not likely — from MoneyControl.com (dated Saturday, India time):
. . . .Merck aims to bring existing products to emerging markets.
While many Merck products were widely available, people were not getting access to them, he said, so it was working with stakeholders to build awareness, healthcare infrastructure and funding platforms, and to improve existing products. . . .
Oh my. Do not — under any circumstance — let actual facts get in the way of the marketing story, here.